Literature DB >> 12496473

Flt-3 ligand: a potent dendritic cell stimulator and novel antitumor agent.

Jian Dong1, Christopher M McPherson, Peter J Stambrook.   

Abstract

Dendritic cell (DC) vaccination has generated intense interest as a potential cancer therapy. However, the rate limiting step has been the generation of DCs. Flt-3 ligand (FL) is a growth factor that was first discovered by its ability to stimulate the proliferation of hematopoietic progenitor cells of both lymphoid and myeloid origin. The remarkable activity of FL to induce large numbers of dendritic cells both in vivo and in vitro soon captured the interest of numerous researchers. In this review, we examine the structure and function of the FL, its antitumor activity in animal models, and its potential as a novel cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12496473     DOI: 10.4161/cbt.1.5.161

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  14 in total

1.  Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.

Authors:  Nicole D Fleming; Robert L Coleman; Celestine Tung; Shannon N Westin; Wei Hu; Yunjie Sun; Priya Bhosale; Mark F Munsell; Anil K Sood
Journal:  Gynecol Oncol       Date:  2017-08-01       Impact factor: 5.482

2.  T cell repertoire scanning is promoted by dynamic dendritic cell behavior and random T cell motility in the lymph node.

Authors:  Mark J Miller; Arsalan S Hejazi; Sindy H Wei; Michael D Cahalan; Ian Parker
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-13       Impact factor: 11.205

Review 3.  Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases.

Authors:  Kenneth Verstraete; Savvas N Savvides
Journal:  Nat Rev Cancer       Date:  2012-10-18       Impact factor: 60.716

4.  Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.

Authors:  Zachary Barnard; Hiroaki Wakimoto; Cecile Zaupa; Anoop P Patel; Jacquelyn Klehm; Robert L Martuza; Samuel D Rabkin; William T Curry
Journal:  Neurosurgery       Date:  2012-09       Impact factor: 4.654

5.  Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice.

Authors:  Qingfeng Chen; Maroun Khoury; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

6.  Efficient production of bioactive recombinant human Flt3 ligand in E. coli.

Authors:  Kenneth Verstraete; Sina Koch; Sevgi Ertugrul; Isabel Vandenberghe; Maarten Aerts; Gonzalez Vandriessche; Christian Thiede; Savvas N Savvides
Journal:  Protein J       Date:  2009-02       Impact factor: 2.371

7.  Barley as a green factory for the production of functional Flt3 ligand.

Authors:  Lýdur S Erlendsson; Marcus O Muench; Ulf Hellman; Soffía M Hrafnkelsdóttir; Anders Jonsson; Yves Balmer; Einar Mäntylä; Björn L Orvar
Journal:  Biotechnol J       Date:  2010-02       Impact factor: 4.677

8.  Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.

Authors:  Michael A Curran; James P Allison
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

9.  Effect of Flt3 ligand gene transfer in experimental pancreatic cancer.

Authors:  E Ryschich; G Huszty; N Wentzensen; E Schmidt; H P Knaebel; J Encke; A Märten; M W Büchler; J Schmidt
Journal:  Int J Colorectal Dis       Date:  2006-03-10       Impact factor: 2.571

Review 10.  Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.

Authors:  Andrew Nguyen; Louisa Ho; Yonghong Wan
Journal:  Front Oncol       Date:  2014-06-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.